AACR 2018: New Liquid Biopsy–Based Cancer Model Reveals Data on Chemoresistance in SCLC
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for why the disease becomes chemoresistant and a possible avenue for exploring new diagnostic approaches.
Findings from the study were presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting in Chicago by Allison Stewart, PhD, Research Scientist in Thoracic Head & Neck Medical Oncology at MD Anderson (Abstract 4938).
“There have been few therapeutic advances in the past 30 years, and platinum-based chemotherapy remains the standard of care [in SCLC]. As a result, 5-year survival is less than 7% across all stages,” said Lauren Byers, MD, Associate Professor of Thoracic Head & Neck Medical Oncology at MD Anderson and the study’s principal investigator. “Most patients respond well to platinum chemotherapy initially but relapse within a few months. There are no highly effective second-line therapies.”
The challenge in studying why and how SCLC chemoresistance occurs is due to the fact that most patients do not undergo another biopsy or surgery at the time of cancer recurrence. This leaves investigators with few SCLC samples with which to conduct genomic and biomarker analyses of drug-resistant tumors.
Disease Models and Sequencing
To overcome the lack of SCLC samples, the team developed novel disease models by isolating circulating tumor cells from a simple blood draw. The cells, placed under the mouse’s skin, develop tumors representative of the patient from whom they were derived. These SCLC models, called circulating tumor cell–derived xenografts (CDX), are unique to each patient and provide an opportunity to assess treatment response to novel targeted therapies, as well as changes that may occur in response to therapy.
“We hypothesize that differences in gene and protein expression between tumor cells, called intratumoral heterogeneity, contribute to the rapid development of platinum chemotherapy resistance,” said Dr. Stewart. “This means that there are likely multiple cell populations in SCLC patients who have not yet been treated. Some of those cells may be killed by chemotherapy, but others will not. These resistant cells then continue to grow and prevent further response to treatment.”
To study intratumoral heterogeneity in SCLC, the investigators performed single-cell sequencing of CDX models to identify gene-expression differences between individual cells from chemotherapy-sensitive CDX tumors compared to those that remain resistant.
“We conducted single-cell RNA sequencing to determine if [intratumoral heterogeneity] exists and to compare response to chemotherapy in the CDX and the patient,” said Dr. Stewart. “We found several distinctions between sensitive and resistant models detected at the single-cell level, which testified to single-cell sequencing’s potential usefulness for understanding how these cancers may develop resistance.”
SCLC has a variety of differences at the cellular and genetic level, from the way genes are expressed to which cell-signaling pathways are involved. These differences between tumor cells result in intratumoral heterogeneity. A more thorough understanding of intratumoral heterogeneity is important to identify populations of cells that may drive certain pathways associated with aggressive resistance to chemotherapy.
Two Key Characteristics
The team also found that SCLC models sensitive to chemotherapy had more cells that expressed two genes, ASCL1 and DLL3, whereas those that were chemoresistant had fewer cells expressing those genes or had undergone a process called epithelial-to-mesenchymal transition, which also has been shown to play a role in treatment resistance in other cancers.
“Cells expressing each of these characteristics were identified across all tumors, suggesting cells sensitive or resistant to chemotherapy are both present in the same tumor,” said Dr. Stewart. “However, even subtle shifts in the distribution of these genes can exert significant impact on response to treatment.”
Dr. Stewart adds that the team’s data support further use of single-cell analysis to explore the role of intratumoral heterogeneity in SCLC, including effects of treatment on cell populations. “Through use of these new mouse models, we report data that supports use of single-cell analysis to explore the role of [intratumoral heterogeneity] as a driver of drug resistance,” she concluded.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
